Kari Grønås
Director/Board Member at SPAGO NANOMEDICAL AB
Net worth: 4 185 $ as of 2024-04-29
Kari Grønås active positions
| Companies | Position | Start | End |
|---|---|---|---|
| SPAGO NANOMEDICAL AB | Director/Board Member | 2017-12-31 | - |
| Independent Dir/Board Member | 2017-12-31 | - | |
| ULTIMOVACS ASA | Director/Board Member | 2018-12-31 | - |
K & K AS
 K & K AS Miscellaneous Commercial ServicesCommercial Services K & K AS manages securities. The company was founded on June 26, 2002 and is headquartered in Oslo, Norway. | Director/Board Member | 2012-05-20 | - |
| Chief Executive Officer | 2012-05-20 | - | |
| Norwegian Cancer Society | Director/Board Member | - | - |
Arxx Therapeutics AS
 Arxx Therapeutics AS BiotechnologyHealth Technology Arxx Therapeutics AS develops therapeutics for fibrotic diseases. The company is based in Oslo, Norway. The Norwegian company was founded in 2015 by Jonas Hallén, Jörg Klingelhöfer. Øystein Soug has been the CEO of the company since 2022. | Director/Board Member | - | - |
Career history of Kari Grønås
Former positions of Kari Grønås
| Companies | Position | Start | End |
|---|---|---|---|
| BERGENBIO ASA | Director/Board Member | 2016-01-31 | 2019-03-12 |
| Independent Dir/Board Member | 2016-01-31 | 2019-03-12 | |
| ONCOPEPTIDES AB | Director/Board Member | - | - |
| SOFTOX SOLUTIONS | Director/Board Member | - | - |
| Norwegian Pharmaceutical Society | Chairman | - | - |
| ░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - | - |
| ░░░░░ ░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
Training of Kari Grønås
| University of Oslo | Graduate Degree |
Statistics
International
| Norway | 11 |
| Sweden | 3 |
Operational
| Director/Board Member | 9 |
| Independent Dir/Board Member | 2 |
| Chief Operating Officer | 1 |
Sectoral
| Health Technology | 8 |
| Commercial Services | 3 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 6 |
|---|---|
| BERGENBIO ASA | Health Technology |
| LYTIX BIOPHARMA | Health Technology |
| SPAGO NANOMEDICAL AB | Health Technology |
| SOFTOX SOLUTIONS | Commercial Services |
| ULTIMOVACS ASA | Health Technology |
| ONCOPEPTIDES AB | Health Technology |
| Private companies | 5 |
|---|---|
Algeta ASA
 Algeta ASA Pharmaceuticals: MajorHealth Technology Algeta ASA is engaged in the development of products for the treatment of cancer. The company focuses on the development of anti-cancer drugs, and its research and development of compounds focuses on the various applications of a few base compounds. Its products, Alpharadin and Thorium-227, are being developed for treatment of skeletal metastases originating from prostate and breast cancer. The company was founded by Roy H. Larsen and Øyvind Sverre Bruland in 1997 and is headquartered in Oslo, Norway. | Health Technology |
| Norwegian Pharmaceutical Society | |
K & K AS
K & K AS Miscellaneous Commercial ServicesCommercial Services K & K AS manages securities. The company was founded on June 26, 2002 and is headquartered in Oslo, Norway. | Commercial Services |
| Norwegian Cancer Society | |
Arxx Therapeutics AS
Arxx Therapeutics AS BiotechnologyHealth Technology Arxx Therapeutics AS develops therapeutics for fibrotic diseases. The company is based in Oslo, Norway. The Norwegian company was founded in 2015 by Jonas Hallén, Jörg Klingelhöfer. Øystein Soug has been the CEO of the company since 2022. | Health Technology |
- Stock Market
- Insiders
- Kari Grønås
- Experience